Heart failure & cardiomyopathies
Guideline-Directed Medical Therapy Use in the STRONG-HF Trial
Authors' conclusion
The GDMT intensity score provides a comprehensive description of medication use by means of standardized measurements and is linked to clinical outcomes. Future studies should consider utilizing this as a trial end point.
Study context
- Population
- Randomized patients in the STRONG-HF trial (heart failure)
- Comparison
- High-intensity care vs usual care: Guideline-directed medical therapies (GDMT) use (GDMT intensity score; basic, indication-corrected and dose-corrected adherence) and association with clinical outcomes up to 180 days
Primary result
As reported in the abstract
Triple therapy indication-corrected use · 90 days
Usual care group
4.5% to 36%
increase
High-intensity care group
5.2% to 93.5%
increase
P < 0.001
Further findings
GDMT intensity score >7 · 90 days
P < 0.0001
| Outcome | Usual care group | High-intensity care group | P value |
|---|---|---|---|
| Triple therapy dose-corrected use · 90 days | increase 4.5% to 20.5% | increase 3.3% to 77.4% | P < 0.001 |
GDMT intensity score at baseline
Patients
- <6
- 358 (33%)
- 6 to 7
- 329 (31%)
- >7
- 386 (36%)
Correlation of GDMT intensity score with clinical outcomes · 180 days
- The GDMT intensity score was correlated with clinical outcomes
Original publication
Guideline-Directed Medical Therapy Use in the STRONG-HF Trial. Circ Heart Fail. Published 3 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →